Study drug for people with acute respiratory distress syndrome
Part of Lungs & breathing clinical trials.
This Phase 2 trial tests GEn-1124 to see if it can improve outcomes in people with acute respiratory distress syndrome (ARDS). You may be eligible if the study drug can be started very soon after ARDS is diagnosed and if you meet the safety and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult age 18 to 85
- Start the study treatment as early as possible after ARDS is diagnosed using the ARDS 2023 definition
- Be able to give informed consent (or have a legal process for consent)
- Use acceptable birth control if there is any chance of pregnancy
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information from ICU patients with or at high risk for ARDS to better understand the condition and develop a tool to help doctors make decisions. It may not directly help you, but it could improve care for future patients.
This trial tests a new medicine called GKL-006RTU for people with moderate to severe ARDS caused by an infection. The goal is to see if it is safe and helps improve breathing and recovery.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This study tests an investigational stem cell treatment called MesenCure for people with acute respiratory distress syndrome (ARDS), a serious lung condition that often occurs with COVID-19. The treatment may help reduce lung inflammation and improve breathing.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
Hear when a new Respiratory Distress Syndrome, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.